Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Cell & Gene Therapy Insights 2019; 6(7), 941–945


Published: 10 August 2020
Janet Lynch Lambert

With this new wave of transformative therapies rushing towards us, payors, policymakers, and other stakeholders must implement the infrastructure necessary to ensure broad patient access and appropriate value-based reimbursement. As the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, the Alliance for Regenerative Medicine (ARM) is laser focused on the legislative, regulatory, and reimbursement initiatives that will incentivize this innovation and help patients access these therapies as quickly as possible post-approval. This article details key priority areas for advancing market access to cell and gene therapies, as well as recent successes and remaining challenges in the USA and Europe.